GUIDELINE FOR THE MANAGEMENT OF HYPEREMESIS GRAVIDARUM IN PREGNANCY

Developed in response to: Intrapartum NICE Guidelines
Contributes to Outcome 4

Consulted With |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Directors</td>
</tr>
<tr>
<td>Dr Rao</td>
</tr>
<tr>
<td>Dr Madhu</td>
</tr>
<tr>
<td>Bernadette Rigdon</td>
</tr>
<tr>
<td>Georgina Sparrow</td>
</tr>
<tr>
<td>Deb Cobie</td>
</tr>
<tr>
<td>Debbie Anderson</td>
</tr>
<tr>
<td>Jan Medici</td>
</tr>
<tr>
<td>Sally Larcombe</td>
</tr>
<tr>
<td>Claire Fitzgerald</td>
</tr>
</tbody>
</table>

Post/Committee/Group |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, Childrens &amp; Sexual Health Division</td>
</tr>
<tr>
<td>Consultant for Obstetrics and Gynaecology</td>
</tr>
<tr>
<td>Consultant for Obstetrics and Gynaecology</td>
</tr>
<tr>
<td>Acting Head of Midwifery Services</td>
</tr>
<tr>
<td>Acting Head of Midwifery Services</td>
</tr>
<tr>
<td>Maternity Risk Management</td>
</tr>
<tr>
<td>Lead Nurse Gynaecology</td>
</tr>
<tr>
<td>Gynaecology Sister Outpatients</td>
</tr>
<tr>
<td>Gynaecology Sister Outpatients</td>
</tr>
<tr>
<td>Pharmacist</td>
</tr>
</tbody>
</table>

Date August 2010

Professionally Approved By |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr Spencer</td>
</tr>
</tbody>
</table>

Clinical Director, Obstetrics & Gynaecology August 2010

Version Number 1.0
Issuing Directorate Obstetrics and Gynaecology
Ratified By Documents Ratification Group
Ratified On 23rd September 2010
Trust Executive Sign Off Date CMB October 2010
Next Review Date September 2013
Author/Contact for Information Dr Wai, Obstetric Registrar
Dr Rao, Consultant Obstetrician

Policy to be followed by (target staff) Midwives, Obstetricians, Paediatricians

Distribution Method Hard copies to all ward areas and managers
Electronic copy to all appropriate staff on email Intranet & Website. Notified on Staff Focus

Related Trust Policies (to be read in conjunction with) 04071 Standard Infection Prevention
04072 Hand Hygiene
06036 Guideline for Maternity Record Keeping including Documentation in Handheld Records
08014 Management of women requiring antenatal thromboprophylaxis

Review No
Reviewed by
Review Date

It is the personal responsibility of the individual referring to this document to ensure that they are viewing the latest version which will always be the document on the intranet.
INDEX

1. Purpose of Guideline
2. Equality and Diversity
3. Definition
4. Pathophysiology
5. Differential Diagnosis
6. Complications Hyperemesis Gravidarum (HG)
7. Management of HG
8. Fluid Therapy
9. Vitamin Supplementation
10. Antiemetic Therapy
11. Corticosteroid
12. Thromboprophylaxis
13. Nutritional Advice
14. Acupuncture and Acupressure
15. Management for Extremely Severe Hyperemesis
16. Enteral Nutrition
17. Total Parenteral Nutrition (TPN)
18. Recurrence in Future Pregnancy
19. Staff and Training
20. Infection Prevention
21. Audit and Monitoring
22. Guideline Management
23. Communication
24. References

25. Appendices

A. Differential Diagnosis
B. Hyponatremia and Central Pontine Myelinolysis
C. Wernicke’s Encephalopathy
D. Summary of Management of Hyperemesis Gravidarum
E. Risk assessment of Venous Thromboembolism (VTE)
F. Pharmacological Group of Anti
G. Recommended Antiemetic Regime
H. Suggested Corticosteroid Regime
1.0 Purpose of Guideline

1.1 This guideline provides guidance in the assessment and management of hyperemesis gravidarum to provide a consistently high standard of care.

2.0 Equality and Diversity

2.1 Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals.

3.0 Definition

3.1 Hyperemesis gravidarum is severe, intractable nausea and vomiting affecting 0.3 -2 % of pregnancies. Nausea and vomiting during pregnancy are extremely common, presenting in 50% to 90% of all gravidae.

3.2 The onset of symptoms is usually early in the first trimester at around 5-8 weeks gestation. Vomiting abates in 90 % of cases by 16 weeks. They may persist beyond 20 weeks in 13% of case.

3.3 Hyperemesis gravidarum (HG) is inconsistently defined. It is typically characterised by severe nausea and vomiting that causes dehydration and imbalance of fluid and electrolyte, disturbs nutritional intake and metabolism, causes physical and psychological debilitation, and often necessitates hospital admission.

4.0 Pathophysiology

4.1 HG is poorly understood and has a complex multifactorial aetiology. HG appears to occur as a complex interaction of biological, psychological, and sociocultural factors.

4.2 Human chorionic gonadotrophin: Prospective studies reported that there was significantly higher level of serum hCG in hyperemesis patients than in controls.

3.2 It is postulated that hCG causes hyperemesis via stimulating effect on secretory process in the upper gastrointestinal tract.

3.3 Oestrogen: One study reported a positive association between nausea and vomiting and maternal serum E2 level.

3.4 It has been proposed that elevated maternal serum steroid hormone causes a decrease in intestinal motility and gastric emptying. This in turn alters gastrointestinal pH and encourages the development of subclinical helicobacter pylori infection.

3.5 Thyroid hormone: In early pregnancy physiological stimulation of thyroid gland occasionally lead to gestational transient thyrotoxicosis.

3.6 Biochemical hyperthyroidism (raised free thyroxine and/or suppressed thyroid stimulating hormone (TSH) may be found in 66% of hyperemesis gravidarum.

3.7 Abnormal thyroid function test do not require treatment with anti-thyroid drugs and resolve as the hyperemesis improves.

3.8 True thyrotoxicosis may present in early pregnancy. Discriminatory features to distinguish
from a gestational syndrome include the presence of tremor, exophthalmos, goitre with bruit and the presence of thyroid stimulating antibodies.

3.9 **Subclinical helicobacter pylori infection:** One study using histological examination of mucosal biopsy reported that 95% of all hyperemesis patients tested positive for subclinical helicobacter pylori infection compared with 50% in the control group.

3.10 **Psychosocial factors:** Various psychological stresses have been linked with hyperemesis, including emotional immaturity, strong mother-dependence, anxiety and tension related to pregnancy, and resentment towards her unwanted pregnancy.

3.11 However, more recent investigations argue that the psychological symptoms are the result of stress arising from physical burden of hyperemesis rather than a cause.

4.0 **Diagnosis**

4.1 Diagnosis of HG is made clinically after exclusion of other causes. Vomiting refractory to treatment and new symptoms appearing after 12 weeks should not be attributed to hyperemesis gravidarum.

4.2 **Clinical features:** Onset of symptoms usually occurs between 4 and 10 weeks

<table>
<thead>
<tr>
<th>Symptoms:</th>
<th>Signs:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>Dehydration</td>
</tr>
<tr>
<td>Vomiting</td>
<td>Weight loss (≥5% of pre-pregnancy)</td>
</tr>
<tr>
<td>Spitting</td>
<td>Ketonuria</td>
</tr>
<tr>
<td>Enhanced olfactory senses</td>
<td>Anaemia</td>
</tr>
<tr>
<td>Food and/or fluid intolerance</td>
<td>Tachycardia</td>
</tr>
<tr>
<td>Lethargy</td>
<td></td>
</tr>
</tbody>
</table>

4.3 **Investigations**

Aim
- to establish the severity of hyperemesis and associated electrolyte derangement
- to exclude other causes of nausea and vomiting

Initial investigations
- Urea and electrolytes
- Liver function test
- Full blood count
- Urinalysis and mid stream urine
- Early ultrasound scan to refer on multiple or molar pregnancies which will increase the incidence of HG

Additional investigations
- Calcium
- Blood glucose
- Thyroid function test
5.0 Differential Diagnosis

5.1 Coexisting pathology that should be considered in women with HG, if it is not responding to supportive treatment. (Refer to Appendix A)

6.0 Complications of HG

6.1 Maternal complications

- Hypokalemia causes lethargy, skeletal muscle weakness and cardiac arrhythmia.
- Hyponatremia and central pontine myelinolysis (Refer to Appendix B)
- Wernickie’s encephalopathy (Refer to Appendix C)
- Vitamin B6/B12 deficiency causes anaemia and peripheral neuropathy.
- Malnutrition
- Mallory-Weiss oesophageal tears
- Venous thromboembolism
- Psychological morbidity

6.2 Fetal complications

- No increased risk of congenital malformations
- Growth restriction
- Wernicke’s encephalopathy is associated with a 40% incidence of fetal death

7.0 Management of HG

7.1 In a systematic review, seven RCT testing different methods of treatment in hyperemesis, there was no treatment shown to be of benefit.

7.2 Therefore, the management is based on: (Refer to Appendix D)

- Correction of dehydration and electrolyte imbalance
- Prophylaxis against recognised complications
- Provision of symptomatic relief

7.3 Admit to hospital if:

- Symptoms are severe despite 24 hours of medication
- There is evidence of dehydration and the patient is ketotic
- A lower threshold for admitting to hospital if the patient has co-existing condition (i.e. diabetes) which can be adversely affected by nausea and vomiting

8.0 Fluid therapy

8.1 Maintaining hydration is crucial in managing hyperemesis. Patients who are unable to tolerate oral fluid and who are ketotic should receive intravenous fluid and electrolyte replacement.

8.2 Sodium chloride 0.9% and Hartmann’s solution are recommended.
8.3 Ready prepared bags of intravenous fluid, including potassium chloride (KCl) can be prescribed according to patient’s serum potassium level. (Refer to Appendix D)

8.4 Sodium chloride 0.9% contains Na⁺ 150 mmol/l; Hartmann’s solution contains Na⁺ 131 mmol/l and K⁺ 5 mmol/l

8.5 Dextrose containing fluid should be avoided except in women with diabetes as neither 5% dextrose nor dextrose saline contain sufficient sodium to correct the commonly associated hyponatraemia.

8.6 High concentration of dextrose may precipitate Wernicke’s encephalopathy.

8.7 Double strength saline should be avoided, even in case of severe hyponatremia.

9.0 Vitamin Supplementation

9.1 Pabrinex 250 mg thiamine oral thiamine is not tolerated.

10.0 Antiemetic Therapy

10.1 There are substantial data from systematic reviews and cohort studies to support the safety of antiemetic in pregnancy and no sign of teratogenicity of drugs studied. The NICE guidelines recommend the use of antiemetic therapy in the treatment of nausea and vomiting in pregnancy.

10.2 They concluded that patients using antiemetics have a better pregnancy outcome than other patients. This may reflect better nutritional status. Antiemetics may be used liberally and safely in pregnancy.

10.3 Patients with severe hyperemesis may require regular parenteral doses of more than one antiemetic to control symptoms.

10.4 Pharmacological group of antiemetics (Refer to Appendix F)

10.5 Ondansetron can be used if hyperemesis is not responding to above antiemesis after discussion with obstetric registrar/consultant on call. Ondansetron 4 mg, 8 hourly orally, intramuscularly (IM) or intravenously (IV).

10.6 Side effects of antiemetics include drowsiness, particularly with phenothiazine and extra pyramidal effects and oculogyric crisis, particularly with metoclopramide and phenothiazines.

10.7 Metoclopramide is not suitable for younger patients (younger than 20 years of age) as acute dystonic reactions involving facial and skeletal muscle spasms and oculogyric crisis are common in younger people.

10.8 These reactions generally occur within few days of starting the treatment and subside within 24 hours of stopping metoclopramide. Procyclidine 5 -10 mg IV or IM will abort dystonic attack.

10.9 Prochlorperazine may cause drowsiness but is less sedating than cyclizine and promethazine. The degree of sedation varies among individuals and depends on the
dose given. The person should avoid driving or performing skilled tasks (e.g. driving).

11.0 Corticosteroid Treatment

11.1 Steroids should be used for intractable hyperemesis which is not responding to above management, after discussion with consultant.

11.2 Steroid should be accompanied by histamine receptor antagonist or proton pump inhibitor to counteract gastric effect of steroid.

11.3 Hydrocortisone 100 mg, twice daily (BD) for 48 hours until the patient is able to tolerate tablets.

11.4 It is followed by prednisolone 30 – 40 mg daily in a single or divided dose. The response is usually rapid.

11.5 Steroids should be discontinued if there is no effect after 2 days.

11.6 Suggested corticosteroid regime
(Refer to Appendix H)

12.0 Thromboprophylaxis

12.1 Hyperemesis is associated with increased risk of venous thromboembolism (VTE) due to dehydration and immobilisation if patients are needed to be hospitalised. Many antenatal VTE events (including fatal) occurs in the first trimester.
(Refer to the guideline for the ‘Management of patients requiring antenatal thromboprophylaxis’; register number 08014)

12.2 Clexane should be given if the risk factor score for VTE is 3 or more.
(Refer to Appendix E)

13.0 Nutrition Advice

13.1 Nil by mouth or suck ice cubes for the first 24 hours until anti-emetics are effective.

13.2 Afterwards, small and frequent dry meals are usually tolerable. Drinking small amount of fluid regularly is important to maintain hydration.

13.3 Eating before getting out of bed and at times when nausea is less severe may reduce severity of nausea and vomiting.

13.4 Try sipping on herbal teas containing ginger, lemon or peppermint.

13.5 A recent trial showed that ginger was therapeutically equivalent to vitamin B6 for improving nausea, dry retching, and vomiting. It also reported no major adverse effect to ginger. All of the trials used at least 1gm of ginger per day as a treatment. The NICE guidelines recommended the use of ginger as an effective means of reducing symptoms of nausea and vomiting.

14.0 Acupuncture/ Acupressure

14.1 Acupressure is the application of pressure at acupuncture site without the use of needles. The Neiguan point or P6 is on the volar aspect of the wrist.
14.2 The NICE guidelines recommend the non pharmacological treatment of P6 (wrist) acupressure to be effective in reducing the symptoms of nausea and vomiting.

15.1 Management Options for Extremely Severe Hyperemesis Gravidarum

15.2 In cases that fail to respond to all of the above therapies:

- Enteral nutrition
- Total parenteral nutrition (TPN)
- Termination of pregnancy

16.0 Enteral Nutrition

16.1 The cost of enteral nutrition is considerably less than that of TPN and it is safer.

16.2 It is successful in patients with meal related nausea and vomiting only.

16.3 But enteral hyperalimentation may be poorly tolerated due to nausea and vomiting and may be even contraindicated because of the risk of aspiration.

16.4 To minimize the risk of aspiration, a nasojejunal feeding tube may be placed beyond the pylorus, but this necessitates radiation exposure for correct position of tube or insertion under endoscopic guidance.

16.5 Poor tolerance to nasogastric tube may lead to consideration of gastrostomy feeding tube.

17.0 Total Parenteral Nutrition (TPN)

17.1 It is very rarely necessary. Because of substantial metabolic, infectious and thrombotic risks, it should be regarded as a measure of last resort.

17.2 Because TPN involves the use of high concentration of glucose, thiamine supplementation is mandatory.

18.0 Recurrence Risk of Hyperemesis Gravidarum

18.1 The risk of recurrence in subsequent pregnancy is 15.2 %. The risk is reduced by a change of paternity.

19.0 Staffing and Training

19.1 All midwifery and obstetric staff must attend yearly statutory training which includes skills and drills training.

19.2 All midwifery and obstetric staff are to ensure that their knowledge and skills are up-to-date in order to complete their portfolio for appraisal.

20.0 Infection Prevention

20.1 All staff should follow Trust guidelines on infection prevention by ensuring that they effectively ‘decontaminate their hands’ before and after each procedure.
20.2 All staff should ensure that they follow Trust guidelines on infection prevention. All invasive devices must be inserted and cared for using High Impact Intervention guidelines to reduce the risk of infection and deliver safe care. This care should be recorded in the Saving Lives High Impact Intervention Monitoring Tool Paperwork (Medical Devices).

21.0 Audit and Monitoring
21.1 The risk management lead will review all risk event forms and complaints. Any immediate training or educational issues relating to lack of compliance with this guideline will be addressed on a one to one basis.
21.2 All incidents and trends analysis will be reviewed at the Maternity Risk Management Group meeting.
21.3 Audit of compliance with this guideline will be undertaken annually in accordance with the Maternity annual audit work plan. The Audit Lead in liaison with the Risk Management Group will identify a lead for the audit.
21.4 The findings of the audit will be reported to the Risk Management Group and an action plan developed to address any identified deficiencies. Performance against the action plan will be monitored by this group on a monthly basis.
21.5 A survey will be considered by the Lead Midwife for Guidelines and Audit, at least annually, to establish staff awareness of how policies should be accessed and the document management process. Any deficiencies identified will inform the staff training programme.

22.0 Guideline Management
22.1 As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust's intranet site.
22.2 Quarterly memos are sent to line managers to disseminate to their staff the most currently approved guidelines available via the intranet and clinical guideline folders, located in each designated clinical area.
22.3 Guideline monitors have been nominated to each clinical area to ensure a system whereby obsolete guidelines are archived and newly approved guidelines are now downloaded from the intranet and filed appropriately in the guideline folders. ‘Spot checks’ are performed on all clinical guidelines quarterly.
22.4 Quarterly Clinical Practices group meetings are held to discuss ‘guidelines’. During this meeting the practice development midwife can highlight any areas for further training; possibly involving ‘workshops’ or to be included in future ‘skills and drills’ mandatory training sessions.

23.0 Communication
23.1 A quarterly ‘maternity newsletter’ is issued to all staff with embedded icons to highlight key changes in clinical practice to include a list of newly approved guidelines for staff to
acknowledge and familiarise themselves with and practice accordingly. Midwives that are on maternity leave or ‘bank’ staff have letters sent to their home address to update them on current clinical changes.

23.2 Approved guidelines are published monthly in the Trust’s Staff Focus that is sent via email to all staff.

23.3 Approved guidelines will be disseminated to appropriate staff quarterly via email.

23.4 Regular memos are posted on the ‘Risk Management’ notice boards in each clinical area to notify staff of the latest revised guidelines and how to access guidelines via the intranet or clinical guideline folders.

24.0 References


Review on hyperemesis gravidarum, Best Practice & Research Clinical Gastroenterology; Vol 21, No.5, pp. 755-769, 2007

James D. Paauw and Alan T. Davis; Hyperemesis in pregnancy; Maternal-Fetal Nutrition during Pregnancy and Lactation; 2010; P 138 – 140

C. Nelson-Piercy, C. Williamson, Gastrointestinal and hepatic disorder, Maternal Medicine, Medical Problems in Pregnancy. 2007, P 172 –1276

Nikos A Kametas, Catherine Nelson-Piercy; Hyperemesis gravidarum, gastrointestinal and liver disease in pregnancy; Obstetrics, Gynaecology and Reproductive Medicine; Volume 18:3; P 69 – 70, March 2008

CKS safe practical clinical answers; www.cks.nhs.uk

Ann-Marie Neill, Catherine Nelson-Piercy; Hyperemesis gravidarum; The Obstetrician & Gynaecologist; Volume 5, Number 4, 2003; P 204 – 207
## Differential Diagnosis

<table>
<thead>
<tr>
<th>System</th>
<th>Diagnosis</th>
<th>Investigation/initial assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genitourinary</strong></td>
<td>UTI</td>
<td>MSU (mid-stream specimen of urine)</td>
</tr>
<tr>
<td></td>
<td>Uraemia</td>
<td>U&amp;E’s (urea and electrolytes)</td>
</tr>
<tr>
<td></td>
<td>Molar pregnancy</td>
<td>Ultrasound of the uterus</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>Gastritis/ peptic ulcer</td>
<td>Helicobacter pylori antibody</td>
</tr>
<tr>
<td></td>
<td>Reflux/ oesophagitis</td>
<td>empirical PPI therapy or endoscopy</td>
</tr>
<tr>
<td></td>
<td>Pancreatitis</td>
<td>amylase, blood glucose, calcium</td>
</tr>
<tr>
<td></td>
<td>Bowel obstruction</td>
<td>plain supine abdominal</td>
</tr>
<tr>
<td><strong>Endocrine</strong></td>
<td>Addison’s disease</td>
<td>U&amp;E, early morning cortisol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Short Synacthen test with ACTH</td>
</tr>
<tr>
<td></td>
<td>Hyperthyroidism</td>
<td>Signs and symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TFTs (thyroid function test), thyroid autoantibodies</td>
</tr>
<tr>
<td></td>
<td>Diabetes ketoacidosis</td>
<td>blood glucose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>urine dipstick for ketones</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>Intracranial tumours</td>
<td>CNS examination</td>
</tr>
<tr>
<td></td>
<td>Vestibular disease</td>
<td>Brain imaging</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CNS examination</td>
</tr>
</tbody>
</table>
Appendix B

Hyponatremia and Central Pontine Myelinolysis

- Hyponatremia (plasma sodium <120 mmol/l) may present with anorexia, headache, nausea, vomiting and lethargy
- More pronounced hyponatremia may lead to central pontine myelinolysis (osmotic demyelination)
- It is a rare complication of HG and may result from severe hyponatremia or from over rapid correction of hyponatremia
- It can cause pyramidal tract signs, spastic quadripareisis, pseudobulbar palsy and impaired consciousness. It may result in personality change, muscle cramps and weakness, confusion, ataxia, drowsiness, diminished reflexes, and convulsion
- Serious symptomatic hyponatremia is medical emergency and should be managed appropriately by skilled personnel, since the treatment may be potentially as dangerous as the condition itself
Wernicke’s Encephalopathy

- It results from vitamin B1 deficiency and is precipitated by intravenous fluid containing high concentration of dextrose
- It is characterised by ophthalmoplegia (typically sixth nerve palsy, diplopia), ataxia and confusion
- Diagnosis of Wernicke’s encephalopathy is clinical and may be confirmed by the finding of a low red cell transketolase, a thiamine dependent enzyme
- MRI may reveal symmetrical lesion around the aqueduct and fourth ventricle, which resolve after treatment with thiamine
- Although thiamine replacement may improve the symptoms of Wernicke’s encephalopathy, if Korsakoff psychosis develops manifest by retrograde amnesia, impaired ability to learn and confabulation, the recovery rate is only about 50%
- Wernicke’s encephalopathy is associated with a 40% incidence of fetal death
Appendix D

Summary for Management of Hyperemesis Gravidarum

- Prolonged nausea & vomiting
- Intolerable to fluid and/or food
- Clinical dehydration
- Ketouria
- Weight loss
- Nausea & vomiting
- History of other medical condition e.g diabetes,
- Consider other differential

**Admission**

Initial assessment
- Temp, Pulse, Resp, BP, Body weight
- U&E
- LFT
- Urinalysis/ MSU
- USS

Additional investigations
- FBC (full blood count)
- Blood glucose
- TFT (thyroid function test)
- Calcium

**Diagnosis**

**Treatment**

Fluid intake output chart
- U&E (urea and electrolytes), LFT (liver function test)
Alternate day if initial results were normal, daily if the results were abnormal

Fluid & electrolyte replacement
- Normal saline/ Hartmann’s
- 3 litres/day
- KCl (potassium/ about 100 mmol/24 hr)

All hyperemesis
- Pabrinex 250 mg thiamine per pair weekly if oral thiamine is not tolerated.
- Clexane (as per protocol)

Antiemetics (1st group)
- 1st line: Cyclizine
  50 mg t.d.s. PO, IM (intramuscularly) or IV (intravenously)
- 2nd line: Prochlorperazine 12.5 mg t.d.s. IM
- Buccastem 3-6mg bd sublingually
- Third line: Metoclopramide 10 mg t.d.s. PO IM or IV

Antiemetics (2nd group)
- Promethazine (phenergan) 25 mg a day IM/oral
- Chlorpromazine 10-25 mg t.d.s.PO
  25 mg t.d.s. IM
- Domperidone 10 mg q.d.s.(4x/day) PO
  30-60 mg b.d.(2x/day) PR

With consultant decision
- Ondansetron 4 - 8 mg b.d. PO, IM or IV
- Hydrocortisone 100 mg b.d. IV for 48 hour and followed by:
- Prednisolone 30-40 mg o.d. PO for one week when eating, then reduce the dose by 5 mg/week

**Intractable hyperemesis**

Other supportive treatment
- Diet & lifestyle (small frequent dry meal, learn to avoid certain scents which make the patient intolerable
- Ginger
- Acupressure/acupuncture

The options for severe hyperemesis who failed to respond to above measures
- enteral nutrition to discuss with gastroenterologist
- parenteral nutrition (TPN) to discuss with gastroenterologist
- termination of pregnancy psychiatric opinion to be sort
## Appendix E

### Risk assessment for Venous Thromboembolism (VTE)

<table>
<thead>
<tr>
<th>Pre-existing risk factors</th>
<th>Tick</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous recurrent VTE</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Previous unprovoked or estrogen related</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Previous VTE provoked</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Family history of VTE</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Known thrombophilia</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Medical comorbidity</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Age (≥ 35 years)</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
<td>1 or 2 *</td>
</tr>
<tr>
<td>Parity (≥ 3)</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Smoker</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Gross varicose vein</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Obstetric risk factors</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Dehydration/ Hyperemesis/ OHSS</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Multiple pregnancy or ART</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transient risk factors</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Current systemic infection</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Immobility</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Surgical procedure in pregnancy</td>
<td></td>
<td>2</td>
</tr>
</tbody>
</table>

Total score

*Score 1 for BMI >30
*Score 2 for BMI >40
### Pharmacological Group of Antiemetics

<table>
<thead>
<tr>
<th>Phenothiazine</th>
<th>Prochlorperazine (stemetil/ buccastem)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chlorpromazine</td>
</tr>
<tr>
<td>Dopamine antagonists</td>
<td>Metoclopramide</td>
</tr>
<tr>
<td></td>
<td>Domperidone (motilium)</td>
</tr>
<tr>
<td>5-HT3 (serotonin)</td>
<td>Ondansetron</td>
</tr>
<tr>
<td>antagonist</td>
<td></td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Cyclizine</td>
</tr>
<tr>
<td>(H1 receptor antagonist)</td>
<td>Promethazine (phenergan)</td>
</tr>
<tr>
<td></td>
<td>Meclozine</td>
</tr>
</tbody>
</table>
### Recommended Antiemetic Regime

| Group One |  | Dose       | Route         |
|-----------|  |------------|---------------|
| First line|  | Cyclizine  | 50 mg t.d.s.  |
|           |  |            | PO, IM or IV  |
| Second line|  | Prochlorperazine (Stemetil) | 12.5 mg t.d.s. |
|           |  | Buccastem | 3-6 mg b.d    |
|           |  |            | IM sublingual  |
| Third line|  | Metoclopramide | 10 mg t.d.s.  |
|           |  |            | PO, IM or IV  |

| Group two: |  |  |
|           |  |  |
|           |  | Promethazine (phenergan) | 25 mg a day |
|           |  | Chlorpromazine | 10-25 mg t.d.s. 25 mg t.d.s. |
|           |  | Domperidone | 20.0 mg qds 30-60 mg qds |
|           |  |            | PO PR |
## Suggested Corticosteroid Regime

<table>
<thead>
<tr>
<th>Hydrocortisone</th>
<th>100 mg B.D</th>
<th>IV for 48 hour and followed by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone</td>
<td>30-40 mg daily</td>
<td>Orally for one week when eating, then reduce the dose by 5 mg per week as follows:</td>
</tr>
<tr>
<td>Dose (mg)</td>
<td>Duration (days)</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Stop</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>